Targeting p53 for adoptive T-cell immunotherapy

Cancer Research

Volumn 58, Issue 12, 1998, Pages 2601-2605

  McCarty, Todd M ^a   Liu, Xiping ^a   Sun, Ji Yao ^a   Peralta, Elizabeth A ^a   Diamond, Don J ^a   Ellenhorn, Joshua D I ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA A2 ANTIGEN; PROTEIN P53;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ANIMALS; GENES, P53; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, SCID; MICE, TRANSGENIC; NEOPLASMS; SUBRENAL CAPSULE ASSAY; SURVIVAL ANALYSIS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, CYTOTOXIC; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0032525876     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Kovach, J. S., Hartmann, A., Blaszyk, H., Cunningham, J., Schaid, D., and Sommer, S. S. Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. Proc. Natl. Acad. Sci. USA, 93: 1093-1096, 1996.
2. Levine, A. J., Momand, J., and Finlay, C. A. The p53 tumour suppressor gene. Nature (Lond.), 351: 453-456, 1991.
3. Vogelstein, B., and Kinzler, K. W. p53 function and dysfunction. Cell, 70: 523-526, 1992.
4. Finlay, C. A., Hinds, P. W., and Levine, A. J. The p53 proto-oncogene can act as a suppressor of transformation. Cell, 57: 1083-1093, 1989.
5. Eliyahu, D., Michalovitz, D., Eliyahu, S., Pinhasi-Kimhi, O., and Oren, M. Wild-type p53 can inhibit oncogene-mediated focus formation. Proc. Natl. Acad. Sci. USA, 86: 8763-8767, 1989.
6. Oldstone, M. B., Tishon, A., Geckeler, R., Lewicki, H., and Whitton, J. L. A common antiviral cytotoxic T-lymphocyte epitope for diverse major histocompatibility complex haplotypes: implications for vaccination. Proc. Natl. Acad. Sci. USA, 89: 2752-2755, 1992.
7. Finlay, C. A., Hinds, P. W., Tan, T. H., Eliyahu, D., Oren, M., and Levine, A. J. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol. Cell. Biol., 8: 531-539, 1988.
8. Yewdell, J. W., and Bennink, J. R. Cell biology of antigen processing and presentation to major histocompatibility complex class I molecule-restricted T lymphocytes. Adv. Immunol., 52: 1-123, 1992.
9. Rosenberg, S. A., Kawakami, Y., Robbins, P. F., and Wang, R. Identification of the genes encoding cancer antigens: implications for cancer immunotherapy. Adv. Cancer Res., 70: 145-177, 1996.
10. Houbiers, J. G., Nijman, H. W., van der Burg, S. H., Drijfhout, J. W., Kenemans, P., van de Velde, C. J., Brand, A., Momburg, F., Kast, W. M., and Melief, C. J. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur. J. Immunol., 23: 2072-2077, 1993.
11. Nijman, H. W., van der Burg, S. H., Vierboom, M. P., Houbiers, J. G., Kast, W. M., and Melief, C. J. p53, a potential target for tumor-directed T cells. Immunol Lett., 40: 171-178, 1994.
12. Ropke, M., Hald, J., Guldberg, P., Zeuthen, J., Norgaard, L., Fugger, L., Svejgaard, A., van der Burg, S., Nijman, H. W., Melief, C. J., and Claesson, M. H. Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-denved peptide. Proc. Natl. Acad. Sci. USA, 93: 14704-14707, 1996.
13. Yu, Z., Liu, X., McCarty, T. M., Diamond, D. J., and Ellenhorn, J. D. I. The use of transgenic mice to generate high affinity p53 specific cytolytic T cells. J. Surg. Res., 66: 337-343, 1997.
14. Theobald, M., Biggs, J., Dittmer, D., Levine, A., and Sherman, L. A. Targeting p53 as a general tumor antigen. Proc. Natl. Acad. Sci. USA, 92: 11993-11997, 1995.
15. Vierboom, M. P., Nijman, H. W., Offringa, R., van der Voort, E. I., van Hall, T., van den Broek, L., Jan Fleuren, G., Kenemans, P., Kast, W. M., and Melief, C. J. Tumor eradication by wild type p53 specific cytotoxic T lymphocytes. J. Exp. Med., 186: 695-703, 1997.
16. Salter, R. D., and Cresswell, P. Impaired assembly and transport of HLA A and B antigens in a mutant TxB hybrid. EMBO J., 5: 943-949, 1986.
17. Fogh, J., Fogh, J. M., and Orfeo, T. One hundred and twenty seven cultured human tumor cell lines producing tumors in nude mice. J. Natl. Cancer Inst. (Bethesda), 59: 221-226, 1977.
18. Klein, E., Ben-Bassat, H., Neumann, H., Ralph, P., Zeuthen, J., Polliack, A., and Vanky, F. Properties of the K562 cell line, derived from a patient with chronic myeloid leukemia. Int. J. Cancer, 18: 421-431, 1976.
19. Lieber, M., Mazzetta, J., Nelson-Rees, W., Kaplan, M., and Todaro, G. Establishment of a continuous tumor-cell line (panc-1) from a human carcinoma of the exocrine pancreas. Int. J. Cancer, 15: 741-747, 1975.
20. Chen, W. H., Horoszewicz, J. S., Leong, S. S., Shimano, T., Penetrante, R., Sanders, W. H., Berjian, R., Douglas, H. O., Martin, E. W., and Chu, T. M. Human pancreatic adenocarcinoma: in vitro and in vivo morphology of a new tumor line established from ascites. In Vitro, 18: 24-34, 1982.
21. Diamond, D. J., York, J., Sun, J. Y., Wright, C. L., and Forman, S. J. Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood, 90: 1751-1767, 1997.
22. Chang, F., Syrjanen, S., and Syrjanen, K. Implications of the p53 tumor-suppressor gene in clinical oncology. J. Clin. Oncol., 13: 1009-1022, 1995.
23. Mayordomo, J. I., Loftus, D. J., Sakamoto, H., DeCesare, C. M., Appasamy, P. M., Lotze, M. T., Storkus, W. J., Appella, E., and DeLeo, A. B. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J. Exp. Med., 183: 1357-1365, 1996.
24. Roth, J., Dittmer, D., Rea, D., Tartaglia, J., Paoletti, E., and Levine, A. J. p53 as a target for vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor challenge. Proc. Natl. Acad. Sci. USA, 93: 4781-4786, 1996.
25. Nijman, H. W., Houbiers, J. G., van der Burg, S. H., Vierboom, M. P., Kenemans, P., Kast, W. M., and Melief, C. J. Characterization of cytotoxic T lymphocyte epitopes of a self-protein, p53, and a non-self-protein, influenza matrix: relationship between major histocompatibility complex peptide binding affinity and immune responsiveness to peptides. J. Immunother., 14: 121-126, 1993.
26. Shapiro, H. M. Precision, sensitivity and accuracy. In: H. M. Shapiro (ed.), Practical Flow Cytometry, pp. 172-174. New York: Wiley-Liss, 1994.
27. Sykulev, Y., Joo, M., Vturina, I., Tsomides, T. J., and Eisen, H. N. Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response. Immunity, 4: 565-571, 1996.
28. Yang, L., Hwang, R., Pandit, L., Gordon, E. M., Anderson, W. F., and Parekh, D. Gene therapy of metastatic pancreas cancer with intraperitoneal injections of concentrated retroviral herpes simplex thymidine kinase vector supernatant and ganciclovir. Ann. Surg., 224: 405-414, 1996.
29. Rosenfeld, M. E., Vickers, S. M., Raben, D., Wang, M., Sampson, L., Feng, M., Jaffee, E., and Curiel, D. T. Pancreatic carcinoma cell killing via adenoviral mediated delivery of the herpes simplex virus thymidine kinase gene. Ann. Surg., 225: 609-618, 1997.